# Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life Conditions

> **NCT03353545** · — · COMPLETED · sponsor: **Genesis Pharma S.A.** · enrollment: 110 (actual)

## Conditions studied

- Relapse/Refractory Multiple Myeloma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03353545
- **Lead sponsor:** Genesis Pharma S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-16
- **Primary completion:** 2020-02-21
- **Final completion:** 2020-02-28
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2021-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03353545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03353545, "Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life Conditions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03353545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*